Amgen Announces Positive Phase III CodeBreaK 300 Data for Sotorasib Combined with Panitumumab in Chemotherapy-Refractory KRAS G12C-Mutated Metastatic Colorectal Cancer

On October 22, Amgen announced the global Phase III CodeBreaK 300 study data for Lumakras (sotorasib, 960mg/240mg) in combination with Vectibix (panitumumab) for the treatment of chemotherapy-refractory KRAS G12C-mutated metastatic colorectal cancer (mCRC). Compared with investigator-selected therapies (trifluridine + tipiracil, or regorafenib), both dose groups of sotorasib + panitumumab demonstrated a statistically significant improvement in progression-free survival (PFS).

CodeBreaK 300 is a randomized, open-label global multicenter Phase III study designed to evaluate the efficacy and safety of sotorasib in combination with panitumumab compared to investigator’s choice of drugs in chemotherapy-refractory KRAS G12C-mutated mCRC patients. The study enrolled 160 participants, who were randomly assigned in a 1:1:1 ratio to receive either sotorasib (960mg) + panitumumab, sotorasib (240mg) + panitumumab, trifluridine + tipiracil, or regorafenib. The primary endpoint is PFS, with secondary endpoints including overall survival (OS) and objective response rate (ORR), among others.

The results showed that, with a median follow-up of 7.8 months, the median PFS was 5.6 months (HR=0.49) for the sotorasib (960mg) + panitumumab group and 3.9 months (HR=0.58) for the sotorasib (240mg) + panitumumab group. The median PFS for subjects receiving the study's selected therapy was 2.2 months. Regarding secondary endpoints, both dose groups also demonstrated clinically meaningful benefits in ORR, disease control rate (DCR), and duration of response (DOR). OS data are not yet mature.

In terms of safety, the most common ≥3 grade treatment-related adverse events (TRAEs) in the sotorasib + panitumumab treatment group were acne-like dermatitis, hypomagnesemia, rash, and diarrhea, with no fatal adverse events occurring.

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article; if you need to reproduce it, please leave a message or send a notification to the WeChat Official Account backend, and include the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

Exciting Preview

Online Live Streaming & Offline Salon